Outset Medical (Nasdaq: OM) to see top lawyer depart in Sept. 2026
Rhea-AI Filing Summary
Outset Medical, Inc. (OM) reports that its General Counsel, John Brottem, has decided to depart from the company and his role, effective September 11, 2026, to pursue other professional opportunities. The company states that his departure is not due to any dispute or disagreement with the company or its management.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Notice date of departure: August 27, 2026
Effective departure date: September 11, 2026
Common Stock par value: $0.001 per share
3 metrics
Notice date of departure
August 27, 2026
Date John Brottem informed the company of his decision to depart
Effective departure date
September 11, 2026
Effective date of General Counsel John Brottem’s departure
Common Stock par value
$0.001 per share
Par value of Outset Medical, Inc. common stock
Key Terms
General Counsel, Emerging growth company, Common Stock, $0.001 par value per share, Section 12(b)
4 terms
General Counsel regulatory
"his role as General Counsel, effective September 11, 2026"
A general counsel is the chief lawyer of an organization, responsible for overseeing all legal matters and ensuring the company complies with laws and regulations. Think of them as the organization's legal advisor or navigator, helping to prevent legal problems before they happen. Their role matters to investors because they help protect the company from legal risks that could impact its success and value.
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) regulatory
"Securities registered pursuant to Section 12(b) of the Act"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
FAQ
What leadership change did Outset Medical (OM) disclose in this 8-K?
Outset Medical disclosed that its General Counsel, John Brottem, has decided to depart from the company and his role, effective September 11, 2026, to pursue other professional opportunities.
When is Outset Medical’s (OM) General Counsel John Brottem leaving the company?
Outset Medical states that General Counsel John Brottem will depart effective September 11, 2026, following his decision communicated to the company on August 27, 2026.
What position did John Brottem hold at Outset Medical (OM)?
John Brottem served as General Counsel of Outset Medical, Inc. before informing the company on August 27, 2026 of his decision to depart.
On which exchange is Outset Medical (OM) listed and under what symbol?
Outset Medical’s Common Stock, $0.001 par value per share, is listed on The Nasdaq Stock Market LLC under the trading symbol OM.
AI-generated analysis. How Rhea-AI works. Not financial advice.
